
ABSTRACT Introduction Invasive papillary carcinoma (IPC) of the breast is an exceptionally rare histological subtype. This study compared the clinicopathological characteristics, biomarker expression profiles and survival outcomes of IPC with those of invasive ductal carcinoma of no special type (IDC‐NST). Materials and Methods The medical records of 6599 patients treated at the Breast Disease Research Center between December 1993 and December 2021 were retrospectively reviewed. Patients were categorized into IPC ( n = 27) and IDC ( n = 6572) groups. Tumour size, axillary lymph node status, pathologic stage, histologic grade, hormone receptor status (ER, PR), HER2 status, surgical management, adjuvant therapies and survival outcomes were analysed and compared. Survival distributions were evaluated using Kaplan–Meier curves and compared using the log‐rank test. Results Patients with IPC were significantly older at presentation than those with IDC (mean age: 58.5 ± 14.0 vs. 49.0 ± 12.4 years, p = 0.02). Compared with IDC, IPC tumours demonstrated significantly less aggressive features, including a lower rate of axillary lymph node involvement (14.8% vs. 39.2%, p < 0.001) and a lower incidence of lymphovascular invasion (14.9% vs. 53.3%, p < 0.001). IPC tumours were predominantly low‐grade (Grade I: 70.3% vs. 20.5%, p < 0.001) and presented more frequently at Stage I (85.1% vs. 39.8%, p < 0.001). Adjuvant chemotherapy was administered significantly less often in the IPC group than in the IDC group (62.9% vs. 94.9%, p < 0.001). In stage‐specific analyses of Stage I disease, IPC exhibited favourable 5‐year disease‐free survival (81% vs. 69%, p = 0.008) and 5‐year overall survival (85% vs. 75%, p = 0.001) compared with Stage I IDC. Conclusion IPC is a rare tumour type that presents unique clinicopathological characteristics and is associated with a higher rate of breast‐conserving surgery and a favourable prognosis than IDC.
ABSTRACT Background Neonatal surgery induces a significant systemic inflammatory response mediated by cytokines such as IL‐6 and CRP. Melatonin has well‐established antioxidant and anti‐inflammatory properties, but data in neonates remain limited. This study aimed to evaluate the effect of adjunctive oral melatonin on serum IL‐6 and CRP levels in neonates undergoing surgery. Methods This randomized, double‐blind, placebo‐controlled trial included 40 neonates under 1 month of age undergoing major abdominal surgery at Mofid Children's Hospital, Tehran (2023–2024). Positive blood culture before surgery was an exclusion criterion. Neonates received oral melatonin (0.1 mg/kg/day, n = 20) or placebo ( n = 20) for 3 days. IL‐6, CRP and WBC were measured at baseline and 72 h after the last dose. Blood cultures were repeated 72 h after surgery. Results Baseline characteristics were comparable. Post‐intervention, the melatonin group showed significantly lower IL‐6 ( p = 0.0102) and CRP ( p = 0.0156) levels compared to placebo. Within‐group analysis revealed that IL‐6 increased significantly in the placebo group ( p = 0.003), whereas the decrease in the melatonin group was not significant ( p = 0.09). CRP reduction was significant in the melatonin group ( p = 0.01) but not in the placebo group ( p = 0.65). WBC counts and hospital stay showed no significant differences. Postoperative positive blood cultures occurred in 35% of the placebo group versus 10% of the melatonin group ( p = 0.118). No adverse events were reported. Conclusion Perioperative melatonin was associated with significantly lower postoperative IL‐6 and CRP levels compared to placebo, with a favourable safety profile. These between‐group differences should be interpreted in the context of the within‐group findings, including the significant postoperative rise in IL‐6 in the placebo group. Larger multicenter trials are needed to confirm these findings.
ABSTRACT Objective To address technical limitations of histotripsy in treating hepatic tumours larger than 3 cm by developing a mathematical framework to optimize treatment coverage while minimizing unsafe overlap. Methodology A theoretical model was constructed using sphere packing and covering principles to estimate the number of smaller treatment zones required to cover a larger tumour volume and applied to a clinical case of a 6 × 6 cm hepatic tumour. Volume ratios were calculated and adjusted using random close packing density (~64%). Results Our model predicted 2.16–4.94 treatment zones for a 6 cm tumour; three overlapping treatments were performed to ensure adequate coverage. Our model suggests that the number of required treatments may increase exponentially with tumour size. Conclusions This framework provides a practical tool for preoperative planning. As tumour size increases, challenges include prolonged procedures, increased anaesthesia exposure and greater resource utilization, especially for tumours exceeding 7 cm. Overlapping treatments may increase risks such as acute kidney injury and vascular thrombosis, necessitating careful patient selection and thorough risk–benefit discussion. Importantly, safety‐limited overlap makes untreated voids within tumours mathematically unavoidable. Thus, our model should not be interpreted as achieving curative intent but can be interpreted as a method for palliative debulking.
ABSTRACT Background Acute cholecystitis is a common surgical condition, most frequently caused by gallstones. Ultrasound is recommended as the first‐line imaging modality, while CT and MRCP are reserved for inconclusive cases or suspected complications. Increasing use of CT in Denmark raises concerns regarding unnecessary radiation exposure. This study evaluated the use of radiological imaging modalities in patients with acute cholecystitis at a Danish regional hospital, including an audit of CT scan justification. Materials and Methods The study population consisted of patients admitted with acute cholecystitis at a Danish regional hospital between March 2019 and February 2023. This retrospective quality assurance study assessed annual incidence, and a random sample of 200 patients was analysed for clinical characteristics and use of imaging modalities. Two independent surgeons evaluated whether CT as the initial imaging modality was justified; disagreements were resolved by consensus. Results Ultrasound was used as the first imaging modality in 54% of patients and as the sole modality in 37%. Overall, 69% of patients underwent only one imaging modality. MRCP was most frequently used as the final modality (40.3%). Murphy's sign was undocumented in 49.2% of cases. Ultrasound was more frequently selected as the initial modality when Murphy's sign was positive (74%) compared with negative (48%) or undocumented (42%). In the CT audit, 16.1% of CT scans were deemed unjustified. Conclusion Ultrasound remains the primary first‐line imaging modality in acute cholecystitis, and documentation of Murphy's sign significantly influences imaging selection. Systematic assessment and documentation of Murphy's sign may improve imaging appropriateness and reduce unnecessary CT use. Notably, approximately one‐sixth of CT scans were unjustified.